321 related articles for article (PubMed ID: 15958824)
1. Factors influencing the immunogenicity of therapeutic proteins.
Schellekens H
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi3-9. PubMed ID: 15958824
[TBL] [Abstract][Full Text] [Related]
2. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery.
Boven K; Knight J; Bader F; Rossert J; Eckardt KU; Casadevall N
Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii33-40. PubMed ID: 15824129
[TBL] [Abstract][Full Text] [Related]
3. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.
Macdougall IC
Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv9-15. PubMed ID: 15827058
[TBL] [Abstract][Full Text] [Related]
4. How to predict and prevent the immunogenicity of therapeutic proteins.
Schellekens H
Biotechnol Annu Rev; 2008; 14():191-202. PubMed ID: 18606364
[TBL] [Abstract][Full Text] [Related]
5. Pure red-cell aplasia and epoetin therapy.
Bennett CL; Luminari S; Nissenson AR; Tallman MS; Klinge SA; McWilliams N; McKoy JM; Kim B; Lyons EA; Trifilio SM; Raisch DW; Evens AM; Kuzel TM; Schumock GT; Belknap SM; Locatelli F; Rossert J; Casadevall N
N Engl J Med; 2004 Sep; 351(14):1403-8. PubMed ID: 15459301
[TBL] [Abstract][Full Text] [Related]
6. [Pure red cell aplasia in erythropoietin therapy in patients with kidney failure].
Opatrný K
Cas Lek Cesk; 2003; 142(12):741-5. PubMed ID: 14746223
[TBL] [Abstract][Full Text] [Related]
7. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk.
Cournoyer D; Toffelmire EB; Wells GA; Barber DL; Barrett BJ; Delage R; Forrest DL; Gagnon RF; Harvey EA; Laneuville P; Patterson BJ; Poon MC; Posen GA; Messner HA;
J Am Soc Nephrol; 2004 Oct; 15(10):2728-34. PubMed ID: 15466278
[TBL] [Abstract][Full Text] [Related]
8. Epoetins: differences and their relevance to immunogenicity.
Haselbeck A
Curr Med Res Opin; 2003; 19(5):430-2. PubMed ID: 13678480
[TBL] [Abstract][Full Text] [Related]
9. Pure red cell aplasia secondary to treatment with erythropoietin.
Locatelli F; Del Vecchio L
J Nephrol; 2003; 16(4):461-6. PubMed ID: 14696747
[TBL] [Abstract][Full Text] [Related]
10. Importance of biologic follow-ons: experience with EPO.
Casadevall N; Rossert J
Best Pract Res Clin Haematol; 2005; 18(3):381-7. PubMed ID: 15792912
[TBL] [Abstract][Full Text] [Related]
11. Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group.
Evens AM; Bennett CL; Luminari S
Best Pract Res Clin Haematol; 2005; 18(3):481-9. PubMed ID: 15792923
[TBL] [Abstract][Full Text] [Related]
12. Pure red-cell aplasia "epidemic"--mystery completely revealed?
Locatelli F; Del Vecchio L; Pozzoni P
Perit Dial Int; 2007 Jun; 27 Suppl 2():S303-7. PubMed ID: 17556324
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin-Associated PRCA: Still an Unsolved Mystery.
Schellekens H; Jiskoot W
J Immunotoxicol; 2006 Sep; 3(3):123-30. PubMed ID: 18958692
[TBL] [Abstract][Full Text] [Related]
14. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).
Macdougall IC; Casadevall N; Locatelli F; Combe C; London GM; Di Paolo S; Kribben A; Fliser D; Messner H; McNeil J; Stevens P; Santoro A; De Francisco AL; Percheson P; Potamianou A; Foucher A; Fife D; Mérit V; Vercammen E;
Nephrol Dial Transplant; 2015 Mar; 30(3):451-60. PubMed ID: 25239637
[TBL] [Abstract][Full Text] [Related]
15. Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body.
Tamilvanan S; Raja NL; Sa B; Basu SK
J Drug Target; 2010 Aug; 18(7):489-98. PubMed ID: 20192653
[TBL] [Abstract][Full Text] [Related]
16. Epoetin-associated pure red cell aplasia: past, present, and future considerations.
McKoy JM; Stonecash RE; Cournoyer D; Rossert J; Nissenson AR; Raisch DW; Casadevall N; Bennett CL
Transfusion; 2008 Aug; 48(8):1754-62. PubMed ID: 18482185
[TBL] [Abstract][Full Text] [Related]
17. Immunologic mechanisms of EPO-associated pure red cell aplasia.
Schellekens H
Best Pract Res Clin Haematol; 2005; 18(3):473-80. PubMed ID: 15792922
[TBL] [Abstract][Full Text] [Related]
18. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.
Boven K; Stryker S; Knight J; Thomas A; van Regenmortel M; Kemeny DM; Power D; Rossert J; Casadevall N
Kidney Int; 2005 Jun; 67(6):2346-53. PubMed ID: 15882278
[TBL] [Abstract][Full Text] [Related]
19. [Pure red cell aplasia as a complication of treatment with recombinant human erythropoietin].
Grzegorzewska AE; Sucharzewska-Tomczak M
Pol Merkur Lekarski; 2004 Oct; 17(100):407-9. PubMed ID: 15690716
[TBL] [Abstract][Full Text] [Related]
20. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin.
Casadevall N
Nephrol Dial Transplant; 2003 Nov; 18 Suppl 8():viii37-41. PubMed ID: 14608000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
